Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
European Urology Open Science|April 27, 2023
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial CarcinomaArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint InhibitorsScott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.
European Urology Open Science|November 13, 2023
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial CarcinomaEnrique Grande, Aristotelis Bamias, Matthew D Galsky, et al.
The New England Journal of Medicine|July 25, 2019
Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaYohann Loriot, Andrea Necchi, Se Hoon Park, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2021
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trialKarim Fizazi, Pablo González Mella, Daniel Castellano, et al.
The Lancet. Oncology|January 14, 2022
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 studyArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
Cancer|November 16, 2021
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920Hamid Emamekhoo, Mark R Olsen, Bradley C Carthon, et al.
European Urology|December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain EndpointEthan M Basch, Mark Scholz, Johann S de Bono, et al.
The Lancet. Oncology|December 15, 2023
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 studyEnrique Grande, José Á Arranz, Maria De Santis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA TrialChung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
Pageof 8